Disc Medicine, INC Form 4 insider transactions

Disc Medicine Director Kevin Bitterman reported the sale of 99,000 shares of common stock over two days in October 2025.

Disc Medicine Director Georges Gemayel was granted 1,000 stock options with an exercise price of $60.34, vesting based on service and future events.

Disc Medicine, Inc. CEO John D. Quisel exercised stock options to acquire 10,000 shares of common stock at $1.01 per share, effective September 9, 2025, under a pre-arranged 10b5-1 plan.

Kevin Bitterman, a Director at Disc Medicine, Inc., sold 2,287 shares of common stock for approximately $139,580 under a pre-arranged trading plan.

Disc Medicine Director Kevin Bitterman sold over 32,000 shares of common stock for approximately $1.9 million through pre-planned transactions.

Disc Medicine Director Kevin Bitterman sold 395 shares of common stock at $60.95 per share under a pre-arranged trading plan.

Disc Medicine, Inc. Director Kevin Bitterman reported the sale of 8,492 shares of common stock at a weighted average price of $61.04, executed under a Rule 10b5-1 trading plan.

Disc Medicine, Inc. Director Kevin Bitterman reported the sale of 42,870 shares of common stock in pre-scheduled transactions in late July 2025.

Disc Medicine, Inc. Director Kevin Bitterman has filed a Form 4 disclosing a planned sale of 664 common shares on July 18, 2025, executed under a Rule 10b5-1 trading plan.

Disc Medicine's Chief Financial Officer, Jean M. Franchi, sold 2,031 shares of common stock for $59 per share on July 17, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Disc Medicine, Inc. Director Nadim Ahmed was granted 20,000 stock options with an exercise price of $57.74, vesting over three years.

Disc Medicine, Inc.'s Chief Financial Officer, Jean M. Franchi, reported the sale of 2,000 shares of common stock for $57.5 per share, executed under a Rule 10b5-1 trading plan.

Disc Medicine, Inc. CEO John D. Quisel executed stock options and subsequently sold a portion of the acquired shares on July 9, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Disc Medicine, Inc.'s CEO and Director, John D. Quisel, completed a pre-scheduled exercise of stock options and subsequent sale of common shares on July 3, 2025, under a Rule 10b5-1 trading plan.

Disc Medicine, Inc.'s Chief Medical Officer, William Jacob Savage, exercised stock options to acquire 32,070 shares of common stock, increasing his beneficial ownership to 88,795 shares.

Disc Medicine's Chief Financial Officer, Jean M. Franchi, sold 2,000 shares of common stock for approximately $52.26 per share on June 16, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

William Richard White, a Director at Disc Medicine, Inc., was granted 10,000 stock options with an exercise price of $50.86, as disclosed in a recent SEC Form 4 filing.

Disc Medicine, Inc. Director Liam Ratcliffe was granted 10,000 stock options with an exercise price of $50.86, aligning his interests with shareholder value.

Disc Medicine, Inc. Director Donald William Nicholson was granted 10,000 stock options with an exercise price of $50.86 per share, aligning his interests with shareholder value.

Disc Medicine, Inc. Director Georges Gemayel was granted 10,000 stock options with an exercise price of $50.86, vesting based on future events.

Disc Medicine, Inc. Director Mark Chin was granted 10,000 stock options with an exercise price of $50.86, vesting based on service and future company events.

Disc Medicine, Inc. Director Kevin Bitterman was granted 10,000 stock options with an exercise price of $50.86, vesting based on continued service.

Disc Medicine, Inc. Director Mona Ashiya has been granted 10,000 stock options with an exercise price of $50.86, subject to specific vesting conditions and an obligation to transfer the economic benefit to OrbiMed entities.

Disc Medicine's Chief Medical Officer, William Jacob Savage, sold 2,996 shares of common stock for $50 per share on June 6, 2025, as part of a pre-established Rule 10b5-1 trading plan.

William Jacob Savage, Chief Medical Officer of Disc Medicine, Inc., reports selling 6,677 shares of common stock at a weighted average price of $50.0417.

William Jacob Savage, Chief Medical Officer of Disc Medicine, Inc., sold 2,100 shares of common stock on May 2, 2025, under a pre-arranged Rule 10b5-1 trading plan.

John D. Quisel, CEO of Disc Medicine, Inc., exercised stock options on April 7, 2025, acquiring 7,000 shares of common stock at $1.01 per share.

Director Mona Ashiya reports indirect sales of Disc Medicine (IRON) common stock through affiliated entities.

OrbiMed Advisors LLC and related entities report the sale of Disc Medicine, Inc. (IRON) common stock at $54.11 per share.

Director Mona Ashiya reports the sale of Disc Medicine (IRON) shares held indirectly through OrbiMed investment partnerships.